About this Research Topic
Despite recent advances in our understanding of cancer biology and the development of related anti-neoplastic treatments, tumor metastasis, tumor recurrence, and treatment resistance are still daunting challenges for affected patients. It is well-established that tumor bulk is composed of very heterogeneous cell populations. The sub-populations of the cells in the tumor microenvironment directly impact the behavior of malignant cells. Unlike tumor bulk RNA sequencing technologies, single-cell sequencing technologies have provided unprecedented insights into the previously unknown cell (sub)-populations and their expression profile. Single-cell sequencing has already demonstrated promising results in highlighting specific sub-populations implicated in tumor recurrence, chemo-radioresistance, and immune resistance.
Besides, the data obtained from single-cell sequencing experiments might potentially determine specific groups of cell populations and expression patterns that can be used to determine the prognosis of patients suffering from malignancy. Combining the data provided via single-cell sequencing platforms with the current and novel anti-neoplastic treatments might be considered a milestone in the precision treatment of patients suffering from malignancy. Indeed, this combination might potentially guide the clinician in selecting a suitable therapeutic regimen based on individual patients’ genomics. This collection welcomes original papers, narrative reviews, systematic reviews, commentary, and case reports on applying single-cell sequencing technologies in cancer treatment and prognosis. The subtopics of interests include but are not limited to:
• The application of single-cell sequencing on cancer tumor microenvironment behavior.
• Single-cell sequencing analyses to identify the culprit cell populations in tumor relapse, metastasis, chemo-radioresistance, and immune resistance.
• Single-cell sequencing analyses to identify specific groups of specific groups of cell populations and expression patterns for the prognosis of cancer patients.
• The combination of single-cell sequencing technologies with novel anti-neoplastic treatments, like inhibitory immune checkpoint blockade and CAR-T cell therapy.
• The combination of single-cell sequencing technologies with conventional anti-neoplastic treatments, like chemotherapy and radiotherapy.
Besides, the data obtained from single-cell sequencing experiments might potentially determine specific groups of cell populations and expression patterns that can be used to determine the prognosis of patients suffering from malignancy. Combining the data provided via single-cell sequencing platforms with the current and novel anti-neoplastic treatments might be considered a milestone in the precision treatment of patients suffering from malignancy. Indeed, this combination might potentially guide the clinician in selecting a suitable therapeutic regimen based on individual patients’ genomics. This collection welcomes original papers, narrative reviews, systematic reviews, commentary, and case reports on applying single-cell sequencing technologies in cancer treatment and prognosis. The subtopics of interests include but are not limited to:
• The application of single-cell sequencing on cancer tumor microenvironment behavior.
• Single-cell sequencing analyses to identify the culprit cell populations in tumor relapse, metastasis, chemo-radioresistance, and immune resistance.
• Single-cell sequencing analyses to identify specific groups of specific groups of cell populations and expression patterns for the prognosis of cancer patients.
• The combination of single-cell sequencing technologies with novel anti-neoplastic treatments, like inhibitory immune checkpoint blockade and CAR-T cell therapy.
• The combination of single-cell sequencing technologies with conventional anti-neoplastic treatments, like chemotherapy and radiotherapy.
Keywords: Single-cell sequencing, neoplasms, precision medicine, tumor heterogeneity, anti-neoplastic therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
